Blood products have future despite recent setbacks
نویسندگان
چکیده
منابع مشابه
Natural products as antifouling compounds: recent progress and future perspectives.
Since early 2008, an increasing number of countries have ratified an international treaty to ban the application of antifouling (AF) coatings based on organotin compounds (eg tributyltin (TBT) and triphenyltin). As a result, the demand for environmentally friendly, non-toxic or low-toxicity AF compounds and technologies (green AF agents) has become an urgent reality. Marine coatings based on Cu...
متن کاملVision and Goals for the Future Recent Progress and Setbacks Elimination of Undernutrition: a Global Deficit in Policies and Priorities
Printing costs were supported by the International Obesity TaskForce. This report is dedicated to the late Mahbub ul Haq, a member of our Commission who inspired us with his vision and reminded us that too often it is the lack of intellectual courage rather than the lack of wisdom which holds us back from reaching up to what the future could achieve. It may be reproduced without prior permissio...
متن کاملDisease transmission by blood products: past, present and future.
Transfusion of blood and blood products has been associated with transmission of infectious agents. However, it is probable that blood products are currently very safe and that pooled virus-inactivated products from remunerated donors are now safer than untreated single voluntary donor components. Although the transmission events of the past and the present are reasonably well understood, relia...
متن کاملRobust warming projections despite the recent hiatus
The recent slowdown or ‘hiatus’ in global average surface air temperature (SAT) rise1–4 has been used in some studies as evidence to argue that current models overestimate the climate response to increasing concentrations of greenhouse gases5,6. Other studies suggest instead that the recent hiatus merely reflects interdecadal variability superimposed on a long-term warming trend2–4,7–9. However...
متن کاملThrombolysis despite recent stroke: a case series.
BACKGROUND AND PURPOSE Thrombolysis in ischemic stroke is contraindicated in patients who have had a stroke within 3 months. However, it is unclear whether thrombolytic therapy is associated with adverse outcomes in this population. We report the characteristics and outcomes of patients treated with systemic recombinant tissue-type plasminogen activator in the context of known or unknown recent...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 1997
ISSN: 1087-0156,1546-1696
DOI: 10.1038/nbt0697-507